Filing Details

Accession Number:
0000950170-24-028795
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-08 17:31:41
Reporting Period:
2024-03-07
Accepted Time:
2024-03-08 17:31:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1582313 Xenon Pharmaceuticals Inc. XENE Pharmaceutical Preparations (2834) 980661854
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1619962 Sherrington Robin 200 - 3650 Gilmore Way
Burnaby A1 V5G 4W8
Evp, Strategy & Innovation No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2024-03-07 1,234 $9.85 9,632 No 4 M Direct
Common Shares Disposition 2024-03-07 215 $45.96 9,417 No 4 F Direct
Common Shares Acquisiton 2024-03-07 7,407 $9.85 16,824 No 4 M Direct
Common Shares Disposition 2024-03-07 1,289 $45.96 15,535 No 4 F Direct
Common Shares Disposition 2024-03-07 1,019 $46.15 14,516 No 4 S Direct
Common Shares Disposition 2024-03-07 6,118 $46.30 8,398 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2024-03-07 1,234 $0.00 1,234 $9.85
Common Shares Stock Option (Right to Buy) Disposition 2024-03-07 7,407 $0.00 7,407 $9.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-03-11 No 4 M Direct
0 2024-03-11 No 4 M Direct
Footnotes
  1. The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
  2. Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations.
  3. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  4. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  5. The shares subject to this option are fully vested and exercisable.